Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Hopes To Convince FDA With Event-Free Survival Data For Mylotarg

Executive Summary

US agency usually uses endpoint of overall survival to assess acute myeloid leukemia drugs; Mylotarg initially garnered accelerated approval in 2000, but was withdrawn when a confirmatory trial failed to show a clinical benefit. Now it's back before the Oncologic Drugs Advisory Committee.

You may also be interested in...



Oncology Endpoint Guidance: US FDA Reaffirms Support For EFS, MRD In Update

Update of 2007 guidance includes discussion on use of newer endpoints and clarifies that oncology endpoints can serve different purposes.

Mylotarg Returns: US FDA Approves Pfizer's Leukemia Drug With Bonus Pediatric Indication

Agency's Oncologic Drugs Advisory Committee had only discussed gemtuzumab as a treatment for adults with acute myeloid leukemia at its July meeting, but labeling includes a pediatric claim based on a 29-patient trial; drug returns to the US market after being withdrawn in 2010 for failure to confirm clinical benefit.

Mylotarg, Event-Free Survival Endpoint Both Get FDA Panel Endorsement

Oncologic Drugs Advisory Committee votes 6-1 that benefits of Pfizer's Mylotarg outweigh risks, positioning drug for return to market after being withdrawn in 2010; vote could also open door for future acute myeloid leukemia products to use event-free survival as endpoint.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS121059

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel